In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts.
Bay n 7133 and Bay L 9139 (Bayer AG, Wuppertal, Fed. Rep. Germany) are new, orally absorbable, antifungal imidazole derivatives. In vitro, Bay n 7133 was comparable to ketoconazole and miconazole when tested against isolates of Candida albicans and Cryptococcus neoformans. Bay L 9139 also was active against these organisms but to a lesser degree than the other imidazoles. LY 121019, an analog of echinocandin B, was also tested. It proved to be the most active antimycotic against C. albicans but the least active against C. neoformans. Optimal results were obtained in tests employing Kimmig's agar, a medium previously described for use in susceptibility tests with antifungal agents.
D000935:Antifungal Agents / Q000494:pharmacology*; D002175:Candida / Q000187:drug effects; D002176:Candida albicans / Q000187:drug effects*; D003454:Cryptococcus / Q000187:drug effects*; D003455:Cryptococcus neoformans / Q000187:drug effects*; D003470:Culture Media; D054714:Echinocandins; D007093:Imidazoles / Q000494:pharmacology*; D007654:Ketoconazole / Q000494:pharmacology; D008825:Miconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000494:pharmacology; D010456:Peptides, Cyclic; D014230:Triazoles / Q000494:pharmacology*
D000935:Antifungal Agents; D003470:Culture Media; D054714:Echinocandins; D007093:Imidazoles; D010455:Peptides; D010456:Peptides, Cyclic; D014230:Triazoles; C038973:BAY-i 9139; D008825:Miconazole; C037494:vibunazole; C042101:cilofungin; D007654:Ketoconazole